Cleveland Clinic | Strategic Alliance Partners

During a Case-Based Roundtable™ event, Beth Faiman, Phd, CNP, and participants discussed the use of combination therapies, including daratumumab, as frontline therapy for patients with transplant-ineligible multiple myeloma.

Enfortumab vedotin plus pembrolizumab elicited durable responses in patients with locally advanced or metastatic urothelial carcinoma who were ineligible for cisplatin.

Beth Faiman, PhD, MSN, APRN-BC, AOCN, discusses the growing need for advanced practitioner provider education and her role with the NP/PA center of excellence.

Beth Faiman, PhD, CNP, discusses reclassifying patients with multiple myeloma, the accelerated approval of teclistamab, and the removal of belantamab mafodotin from the US market.

The state-of-the-art facility represents the organization’s vision of global cancer care

Aaron T. Gerds, MD, MS, unpacks data seen with momelotinib for patients with anemic myelofibrosis.

Laura Wood discusses the successful integration of avelumab, erdafitinib, and enfortumab vedotin-ejfv into oncology nursing practice.

Avelumab, erdafitinib, and enfortumab vedotin-ejfv are 3 critical drugs in the treatment of urothelial cancer with distinct safety profiles, according to a presentation at the 6th Annual School of Nursing Oncology™ Meeting.

In a presentation at the 6th Annual School of Nursing Oncology™, Laura Wood, RN, MSN, OCN, highlights key nurse takeaways with VEGF TKI/immune checkpoint inhibitor therapy for patients with renal cell carcinoma.

Oncology nurses found that the use of a flexible catheter for subcutaneous immunotherapy is linked with increased safety and satisfaction.

Patients who underwent surveillance with bioimpedance spectroscopy were less likely to develop chronic breast cancer–related lymphedema compared with patients who were assessed with tape measure.

A presentation at the 2021 ASH Annual Meeting revealed a significant association between elevated white blood counts and thrombotic events among patients with polycythemia vera and controlled hematocrit levels.

Recently approved combination therapies have contributed to significantly improved survival rates in renal cell carcinoma.

CAR T-cell therapy may change the treatment paradigm for relapsed/refractory myeloma.

An expert discusses recent advancements in the mantle cell lymphoma space.

It is imperative that patients diagnosed with blood cancer undergo the proper molecular testing, one expert says.

Stereotactic body radiation therapy (SBRT) is highly effective, and potentially curable for early-stage lung cancer, though not many physicians use the therapy, says expert Molly Freeman, CNP.

Laura Wood on collaboration between departments when treating patients with cancer who are receiving immunotherapy treatments.

Molly Freeman explains why it is necessary for providers to be educated on stereotactic body radiation therapy.

Molly Freeman, CNP, discusses the aftercare that goes into treating patients with lung cancer who have undergone stereotactic body radiation therapy (SBRT).